Showing results (71-80 of 790) with videos related to
Sort By:
Pageof 79
Expert Opinion on Drug Safety|November 15, 2016
Safety of proteasome inhibitors for treatment of multiple myelomaDanielle Schlafer, Katherine S Shah, Elyse Hall Panjic, et al.Clinical Lymphoma, Myeloma & Leukemia|June 22, 2013
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapyJonathan L Kaufman, Claire Fabre, Sagar Lonial, et al.Blood|April 4, 2015
Treatment options for relapsed and refractory multiple myelomaAjay K Nooka, Efstathios Kastritis, Meletios A Dimopoulos, et al.Clinical Pharmacology : Advances and Applications|August 26, 2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and SelinexorNisha S Joseph, Yu-Tzu Tai, Kenneth C Anderson, et al.Cancer Biology & Therapy|September 26, 2003
Signal transduction and myeloma: new targets, new hopeSagar Lonial, Edmund K Waller, Jonathan W Simons, et al.Blood Advances|January 4, 2018
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myelomaShardule P Shah, Ajay K Nooka, Sagar Lonial, et al.Hematology/Oncology Clinics of North America|October 25, 2020
Systemic Amyloidosis Due to Clonal Plasma Cell DiseasesGiada Bianchi, Shaji KumarOncology (Williston Park, N.Y.)|September 5, 2014
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myelomaAbhishek Singla, Shaji KumarPageof 79